Trial Profile
A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog in Type 1 Diabetes Mellitus Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Sponsors Mylan
- 17 Sep 2022 Results published in the BioDrugs
- 29 Jun 2021 Primary endpoint has been met (Treatment Emergent Antibody Response (TEAR)) , according to Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association